Palisade Bio is fortifying its brand image. The California-based biotech unveiled a new logo and website design, while also doubling down on its commitment to advancing its lead candidate in ulcerative colitis.
Palisade’s new branding takes on a bolder and brighter look than its original imagery. The refreshed logo is an angular letter “P” infused with vibrant shades of blue and orange. The company’s name, now in all-lowercase, appears in those same shades next to the logo.
The bright hues carry over to Palisade’s renewed website, which is done up in a bold, sans-serif font and features dynamic graphics and backgrounds that move across the page while scrolling, as well as its updated corporate presentation (PDF).
In contrast, Palisade’s previous branding took a more subdued tone. The logo featured the company’s name in all caps, next to a shield-shaped logo that combined the letters “P” and “B,” all in muted shades of orange and dark green. The website, meanwhile, featured static images and a more staid serif font over a gray background.
In a statement Monday, CEO J.D. Finley suggested that the makeover better matches up Palisade’s branding with its goal of creating next-generation medicines.
“We remain committed to our mission of developing differentiated product candidates for immune, inflammatory and fibrotic diseases in established commercial markets where there is a significant unmet medical need. As we continue to advance our pipeline programs, enhance our growing body of data, and build momentum toward value-driving milestones, we believed it was essential to align our corporate brand to clearly reflect the overarching vision we have for Palisade Bio,” Finley said.
“We believe that next-generation precision therapies will be vital in targeting these diseases, and our focus is on advancing our programs to be able to help the millions of patients living with them every day,” he continued. “The data we have collected to date continues to reinforce our confidence as we advance toward several key clinical and regulatory milestones. I am excited for this next phase of evolution and the opportunity to unlock the full potential value of Palisade Bio.”
Palisade, which was formed in late 2020 upon the merger of Seneca Biopharma and Leading BioSciences, currently has two therapies in development, both targeting the inflammatory bowel disease market. Its lead candidate, PALI-2108, is targeting moderate-to-severe ulcerative colitis and, according to the company’s website, is “rapidly advancing” toward dosing its first patient in a phase 1 trial, which Palisade is aiming to begin before the end of the year.
Earlier this year, studies presented at the annual Digestive Disease Week conference in Washington, D.C., showed that PALI-2108 was effective in mouse models of colitis and was also proven to be nontoxic in dogs.
Meanwhile, the biotech is also developing PALI-1908, which is still in the discovery phase and has “significant overlap” with the lead candidate, and which will target fibrostenotic Crohn’s disease.
Palisade recently had to start from scratch in building out its pipeline after Leading BioSciences’ LB1148, which was Palisade’s lead and only candidate after the merger, failed its phase 2 trial last year in patients who were undergoing bowel resection surgery.